Windsor Private Capital Lp Sells 40,139 Shares of Firefly Neuroscience (NASDAQ:AIFF) Stock

Firefly Neuroscience, Inc. (NASDAQ:AIFF) major shareholder Windsor Private Capital Lp sold 40,139 shares of Firefly Neuroscience stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $2.65, for a total value of $106,368.35. Following the sale, the insider owned 1,412,562 shares of the company’s stock, valued at approximately $3,743,289.30. This trade represents a 2.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Windsor Private Capital Lp also recently made the following trade(s):

• On Friday, October 17th, Windsor Private Capital Lp sold 45,036 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.55, for a total transaction of $114,841.80.
• On Wednesday, October 15th, Windsor Private Capital Lp sold 17,500 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.74, for a total transaction of $47,950.00.
• On Tuesday, October 14th, Windsor Private Capital Lp sold 29,500 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.74, for a total transaction of $80,830.00.
• On Monday, October 13th, Windsor Private Capital Lp sold 32,136 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.65, for a total transaction of $85,160.40.
• On Friday, October 10th, Windsor Private Capital Lp sold 74,810 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.70, for a total transaction of $201,987.00.
• On Thursday, October 9th, Windsor Private Capital Lp sold 30,126 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.94, for a total transaction of $88,570.44.

Firefly Neuroscience Stock Performance

Firefly Neuroscience stock opened at $2.51 on Friday. The company has a market capitalization of $33.76 million, a PE ratio of -1.00 and a beta of 2.11. The company has a 50 day moving average price of $2.78 and a 200-day moving average price of $2.97. Firefly Neuroscience, Inc. has a fifty-two week low of $1.86 and a fifty-two week high of $17.20.

Firefly Neuroscience (NASDAQ:AIFF) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter. Firefly Neuroscience had a negative return on equity of 464.02% and a negative net margin of 5,335.75%.

Institutional Trading of Firefly Neuroscience

An institutional investor recently raised its position in Firefly Neuroscience stock. Geode Capital Management LLC raised its stake in shares of Firefly Neuroscience, Inc. (NASDAQ:AIFF) by 92.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 120,604 shares of the company’s stock after acquiring an additional 58,067 shares during the quarter. Geode Capital Management LLC owned approximately 0.94% of Firefly Neuroscience worth $341,000 at the end of the most recent reporting period. 4.96% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Firefly Neuroscience in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Firefly Neuroscience presently has a consensus rating of “Sell”.

Firefly Neuroscience Company Profile

Firefly Neuroscience, Inc, a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder.